34.13
Phibro Animal Health Corp stock is traded at $34.13, with a volume of 293.66K.
It is up +2.62% in the last 24 hours and up +5.24% over the past month.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
See More
Previous Close:
$33.26
Open:
$33.26
24h Volume:
293.66K
Relative Volume:
0.83
Market Cap:
$1.38B
Revenue:
$1.46B
Net Income/Loss:
$92.09M
P/E Ratio:
15.13
EPS:
2.2555
Net Cash Flow:
$47.29M
1W Performance:
+7.29%
1M Performance:
+5.24%
6M Performance:
-13.68%
1Y Performance:
+21.89%
Phibro Animal Health Corp Stock (PAHC) Company Profile
Name
Phibro Animal Health Corp
Sector
Phone
201-329-7300
Address
GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ
Compare PAHC vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PAHC
Phibro Animal Health Corp
|
34.13 | 1.27B | 1.46B | 92.09M | 47.29M | 2.2555 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Phibro Animal Health Corp Stock (PAHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Jul-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-16-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-10-24 | Initiated | JP Morgan | Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Underperform |
| Dec-21-22 | Initiated | ROTH Capital | Buy |
| Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-07-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Aug-06-20 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Jan-28-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-29-19 | Reiterated | BofA/Merrill | Underperform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| May-23-19 | Initiated | Guggenheim | Neutral |
| May-09-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-23-17 | Resumed | BofA/Merrill | Underperform |
| Jun-02-17 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-15-16 | Initiated | Piper Jaffray | Overweight |
| Nov-11-16 | Downgrade | Macquarie | Neutral → Underperform |
| Nov-10-16 | Downgrade | Gabelli & Co | Buy → Hold |
| Apr-11-16 | Reiterated | Guggenheim | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Jan-15-16 | Downgrade | Barclays | Overweight → Underweight |
| Sep-30-15 | Initiated | Gabelli & Co | Buy |
| Apr-24-15 | Reiterated | Barclays | Overweight |
| Apr-21-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-06-14 | Initiated | Barclays | Overweight |
View All
Phibro Animal Health Corp Stock (PAHC) Latest News
Q1 Rundown: Phibro Animal Health (NASDAQ:PAHC) Vs Other Branded Pharmaceuticals Stocks - Yahoo Finance
Wall Street Analysts Predict a 36.23% Upside in Phibro (PAHC): Here's What You Should Know - Yahoo! Finance Canada
Phibro Animal Health Corporation(NasdaqGM: PAHC) dropped from Russell 3000E Index - marketscreener.com
Phibro Animal Health Corporation(NasdaqGM: PAHC) dropped from Russell Microcap Index - marketscreener.com
Phibro Animal Health Corporation 8-K Filing June 2026: Key Details, Trading Symbol, and Company Information - Minichart
Daniel Bendheim named CEO and President of Phibro Animal Health - TradingView
New Phibro (NASDAQ: PAHC) CEO granted 300,000 performance-based RSUs - Stock Titan
Phibro Animal Health Corp (PAHC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phibro Animal Health Corp (PAHC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Paws and profits: adoro Pet Insurance names chief business development officer and other updates - DVM360
PAHC News | PHIBRO ANIMAL HEALTH CORP-A (NASDAQ:PAHC) - ChartMill
PAHC - Finviz
Phibro Animal Health Corp (PAHC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phibro Animal Health Corp (PAHC) Institutional Confidence - TradingKey
Phibro Animal Health Corp (PAHC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phibro Animal Health Corp (PAHC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phibro Animal Health Corp (PAHC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phibro Animal Health Corp (PAHC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phibro Animal Health Corp (PAHC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
What Makes Phibro (PAHC) a New Buy Stock - Yahoo Finance
[144] PHIBRO ANIMAL HEALTH CORP SEC Filing - Stock Titan
Should You Continue to Hold PAHC Stock in Your Portfolio? - Yahoo Finance
Is Beaten-Down Phibro Animal Health Stock a Buy Following an Insider Purchase of 10,000 Shares? - Yahoo Finance
PAHC Stock: What's Driving Phibro's Animal Health Growth - Yahoo Finance
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now? - Yahoo Finance
Phibro Animal Health Corp (PAHC) Stock Price Today & Analysis - Gotrade
Phibro Animal Health (PAHC) Q3 2026 Earnings Call Transcript - MLQ.ai
How The Story Is Shifting For Phibro Animal Health (PAHC) As Analysts Reset Fair Value - Yahoo Finance
A Look At Phibro Animal Health (PAHC) Valuation After Recent Share Price Volatility - simplywall.st
Why Phibro Animal Health (PAHC) Stock Is Trading Up Today - Yahoo Finance
Phibro Animal Health Up 10% After Insider Move - Bez Kabli
Phibro Animal Health director E. Thomas Corcoran buys $317,700 in stock By Investing.com - Investing.com South Africa
Phibro Animal Health director E. Thomas Corcoran buys $317,700 in stock - Investing.com UK
Phibro Animal Health (PAHC) director buys 10,000 shares in market - Stock Titan
Phibro (PAHC) Q3 2026 Earnings Transcript - AOL.com
Phibro Animal Health Lifts Outlook Amid Strong Q3 - TipRanks
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock - Yahoo Finance
Implied Volatility Surging for Phibro Stock Options - Yahoo Finance
Phibro Animal Health Corp (PAHC) Shares Fall 3.1% -- GF Value Sa - GuruFocus
After Plunging 38.0% in 4 Weeks, Here's Why the Trend Might Reverse for Phibro (PAHC) - Yahoo Finance
Should Value Investors Buy Phibro Animal Health (PAHC) Stock? - Yahoo Finance
Phibro's CEO transition puts this insider sale in context - AOL.com
Phibro's CEO transition puts this insider sale in context - The Motley Fool
Phibro Animal Health Corp Stock (PAHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phibro Animal Health Corp Stock (PAHC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CORCORAN E THOMAS | Director |
May 29 '26 |
Buy |
31.77 |
10,000 |
317,700 |
41,459 |
| BENDHEIM JACK | President and CEO |
May 06 '26 |
Sale |
57.37 |
7,040 |
403,850 |
60,680 |
| BENDHEIM JACK | President and CEO |
May 05 '26 |
Sale |
55.80 |
7,040 |
392,810 |
67,720 |
| BENDHEIM JACK | President and CEO |
May 07 '26 |
Sale |
48.49 |
4,528 |
219,568 |
56,152 |
| BENDHEIM JACK | President and CEO |
Apr 28 '26 |
Sale |
55.91 |
7,040 |
393,575 |
88,840 |
| BENDHEIM JACK | President and CEO |
Apr 29 '26 |
Sale |
52.92 |
7,040 |
372,553 |
81,800 |
| BENDHEIM JACK | President and CEO |
Apr 30 '26 |
Sale |
52.76 |
7,040 |
371,465 |
74,760 |
| BENDHEIM JACK | President and CEO |
Apr 21 '26 |
Sale |
55.98 |
7,040 |
394,081 |
109,960 |
| BENDHEIM JACK | President and CEO |
Apr 22 '26 |
Sale |
54.29 |
7,040 |
382,185 |
102,920 |
| BENDHEIM JACK | President and CEO |
Apr 23 '26 |
Sale |
54.09 |
7,040 |
380,826 |
95,880 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):